Sage Makes Deep Cuts, Axing 53% Of The Workforce, As It Reins In Zulresso
Executive Summary
The company will cut 340 positions, primarily affecting Zulresso commercial operations, to save $170m, after announcing it will need to run new trials to support the regulatory plan for zuranolone.
You may also be interested in...
Keeping Track: RSV Vaccine Race Heats Up Between Pfizer And GSK; Another J&J Bispecific For Myeloma
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
Sage/Biogen See Big Potential Market For Zuranolone In PPD
The companies reported positive Phase III data in postpartum depression, a market opportunity of up to half a million women in the US with a condition that remains underdiagnosed.
Biogen/Sage’s Zuranolone Data May Not Be Enough For Tough Commercial Landscape
The drug may have enough efficacy for approval, but data fell short of the benchmark seen as necessary for commercial adoption